Related Experiment Videos
Vitamin E deficiency in Werdnig-Hoffmann disease
Insights
Infants with Werdnig-Hoffmann disease (WHD) show significantly lower vitamin E levels, suggesting a potential role for this deficiency in the disease
Area of Science:
- Neurology
- Biochemistry
Background:
- Neuromuscular disorders affect infants and children.
- Vitamin E is a crucial antioxidant.
Purpose of the Study:
- To investigate vitamin E levels in children with neuromuscular disorders.
- To explore the relationship between vitamin E deficiency and Werdnig-Hoffmann disease (WHD).
Main Methods:
- Plasma vitamin E levels were measured in infants and children.
- Patients included those with WHD, congenital myopathies, and muscular dystrophy.
- A therapeutic trial of vitamin E was conducted in WHD patients.
Main Results:
- Seven out of eight infants with WHD exhibited significantly lower plasma vitamin E levels compared to controls (p < 0.01).
- Vitamin E deficiency in WHD was not attributed to malabsorption.
- Vitamin E supplementation did not alter the disease's progression in three WHD patients.
Conclusions:
- Low vitamin E levels are a characteristic finding in Werdnig-Hoffmann disease.
- Vitamin E deficiency may be implicated in the pathogenesis of WHD.
- Further research is needed to understand the role of vitamin E in WHD.
Abstract:
Vitamin E levels were measured in the plasma of infants and children with various neuromuscular disorders. Seven of 8 infants with Werdnig-Hoffmann disease (WHD) had a significantly lower plasma vitamin E level (p less than 0.01) than age-matched normal controls, children with congenital myopathies, or children with muscular dystrophy. Vitamin E deficiency in WHD is not caused by malabsorption. A therapeutic trial of vitamin E in 3 patients with WHD did not change the natural course of the disease. Vitamin E deficiency may play a role in the pathogenesis of WHD.